News


All series


All News

In a presentation at the&nbsp;35th annual CFS, Edward S. Kim, MD, discussed the &quot;renaissance&quot; in the&nbsp;non&ndash;small cell lung cancer landscape that has come with the rapid evolution of targeted treatment for patients with&nbsp;<em>EGFR</em>-mutation&ndash;positive disease.

Chimeric antigen receptor T cells have hit the prime time, with 2 FDA approvals already for this class of cellbased therapy. Undoubtedly this will be a game changer for patients with B-cell malignancies who have a small number of treatment options; however, questions regarding the realworld application of CAR T-cell therapies remain.

Brentuximab vedotin&nbsp;(Adcetris) has been submitted for FDA approval in combination with Adriamycin, vinblastine, dacarbazine for the frontline treatment of patients with&nbsp;advanced classical Hodgkin lymphoma.&nbsp;Seattle Genetics,&nbsp;the company developing brentuximab vedotin, recently announced the submission of a&nbsp;supplemental new drug application for the&nbsp;CD30-targeted antibody-drug conjugate.

Although the addition of pazopanib (Votrient) to gemcitabine in the second-line treatment of&nbsp;patients with metastatic or relapsed uterine or soft tissue leiomyosarcomas demonstrated disease control in the majority of patients,&nbsp;statistical endpoints were not met in the&nbsp;phase II UNICANCER SARCOMA 11 study, according to results reported at the 2017 ESMO Congress.

In a presentation during the 2017 International Liver Cancer Association Annual Conference, Amit G. Singal, MD, discussed data surrounding the use of direct acting antivirals, a novel and completely oral hepatitis C therapy, which has been associated with a high response rate.

Researchers in the Perelman School of Medicine at the University of Pennsylvania evaluated the genetic profiles of 160 breast and ovarian cancers associated with germline mutations in&nbsp;<em>BRCA1 </em>and <em>BRCA2&nbsp;</em>and determined that there is a relationship between the genetics of <em>BRCA 1/2 </em>mutations and the risk of resistance to platinum-based chemotherapy.&nbsp;

Coordinating appointments between the physician office suite and infusion center improved dramatically with the use of a scheduling optimization tool at the Cowell Family Cancer Center in Traverse City, Michigan. Specifically, the investigators observed a 6% reduction in median office-visit time and a 43% reduction in patient wait time in the infusion chair before infusion began.

According to phase II results from the DSMM XI trial published in the <em>British Journal of Haematology</em>, induction therapy with bortezomib (Velcade), cyclophosphamide, and dexamethasone demonstrated an overall response rate of 85.4%&nbsp;in treatment-na&iuml;ve patients with multiple myeloma.

Medical oncologist Linda T. Vahdat, MD, MBA, has been appointed the new chief of medical oncology and clinical director of cancer services at Norwalk Hospital. The new position comes as a result of a new collaboration between Memorial Sloan Kettering Cancer Center and Norwalk Hospital in Norwalk, Connecticut.

Four researchers from the Dana-Farber Cancer Institute are joining the Parker Institute for Cancer Immunotherapy as a result of a collaboration between the 2 institutions: W. Nick Haining, BCh, BM; Catherine Wu, MD; Philip Kranzusch, PhD; and F. Stephen Hodi, Jr., MD.

A supplemental New Drug Application for olaparib (Lynparza) has been granted a priority review by the FDA for the&nbsp;treatment of patients with germline <em>BRCA</em>-positive, HER2-negative metastatic breast cancer who have previously received chemotherapy in the neoadjuvant, adjuvant, or metastatic settings,&nbsp;AstraZeneca and Merck, the co-developers of the PARP inhibitor, recently announced.

The CD19-directed CAR T-cell therapy&nbsp;axicabtagene ciloleucel (axi-cel; Yescarta) has been approved by the FDA for the treatment of adults with relapsed or refractory non-Hodgkin lymphoma (NHL), based on complete remission (CR) rate results from the phase II ZUMA-1 trial.

Abemaciclib (Verzenio) failed to meet its primary endpoint of improving overall survival versus erlotinib (Tarceva) in patients with&nbsp;<em>KRAS</em>-mutated, advanced non&ndash;small cell lung cancer who progressed after platinum-based chemotherapy, according to topline results from the phase III JUNIPER trial.